GlassScriptPhysician profile
Alexandr Karimov
NPI 1265882195
$5,962.57
in general payments reported to CMS, 2019-2025
37 companies · $1,698 in 2025
The $1,698 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $13.57 · 2021: $57.54 · 2022: $244 · 2023: $922 · 2024: $2,153 · 2025: $1,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,523 · Consulting Fee: $150 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,522.77 |
| Consulting Fee | $150.00 |
| Education | $100.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,604.80 | 2022-2025 | |
| Biogen, INC. | $704.45 | 2024-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $428.95 | 2019-2025 | |
| Pfizer INC. | $352.93 | 2023-2025 | |
| Argenx US, INC. | $330.22 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $306.91 | 2019-2020 | |
| Eisai INC. | $276.02 | 2019-2025 | |
| Lilly USA, LLC | $174.44 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $149.17 | 2023-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $143.19 | 2022 | |
| Genzyme Corporation | $134.95 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $133.50 | 2021-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $104.33 | 2024-2025 | Ingrezza |
| Kyowa Kirin, INC. | $103.21 | 2022-2024 | Nourianz |
| Greenwich Biosciences, INC. | $102.68 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandr Karimov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.